Identification of nine genes as novel susceptibility loci for early-onset ischemic stroke, intracerebral hemorrhage, or subarachnoid hemorrhage

YOSHIJI YAMADA1,2, KIMIHIKO KATO1,3, MITSUTOSHI OGURI1,4, HIDEKI HORIBE5, TETSUO FUJIMAKI6, YOSHIKI YASUKOCHI1,2, ICHIRO TAKEUCHI2,7,8 and JUN SAKUMA2,8,9

1Department of Human Functional Genomics, Advanced Science Research Promotion Center, Mie University, Tsu, Mie 514-8507; 2CREST, Japan Science and Technology Agency, Kawaguchi, Saitama 332-0012; 3Department of Internal Medicine, Meitoh Hospital, Nagoya, Aichi 465-0025; 4Department of Cardiology, Kasugai Municipal Hospital, Kasugai, Aichi 486-8510; 5Department of Cardiovascular Medicine, Gifu Prefectural Tajimi Hospital, Tajimi, Gifu 507-8522; 6Department of Cardiovascular Medicine, Northern Mie Medical Center Inabe General Hospital, Inabe, Mie 511-0428; 7Department of Computer Science, Nagoya Institute of Technology, Nagoya, Aichi 466-8555; 8RIKEN Center for Advanced Intelligence Project, Tokyo 103-0027; 9Computer Science Department, College of Information Science, University of Tsukuba, Tsukuba, Ibaraki 305-8573, Japan

Received April 30, 2018; Accepted May 23, 2018

DOI: 10.3892/br.2018.1104

Correspondence to: Professor Yoshiji Yamada, Department of Human Functional Genomics, Advanced Science Research Promotion Center, Mie University, 1577 Kurima-machiya, Tsu, Mie 514-8507, Japan
E-mail: yamada@gene.mie-u.ac.jp

Key words: ischemic stroke, intracerebral hemorrhage, subarachnoid hemorrhage, genetics, exome-wide association study

Abstract. Given that substantial genetic components have been shown in ischemic stroke, intracerebral hemorrhage (ICH), and subarachnoid hemorrhage (SAH), heritability may be higher in early-onset than late-onset individuals with these conditions. Although genome-wide association studies (GWASs) have identified various genes and loci significantly associated with ischemic stroke, ICH, or intracranial aneurysm mainly in European ancestry populations, genetic variants that contribute to susceptibility to these disorders remain to be identified definitively. We performed exome-wide association studies (EWASs) to identify genetic variants that confer susceptibility to ischemic stroke, ICH, or SAH in early-onset subjects with these conditions. A total of 6,649 individuals aged ≤65 years were examined. For the EWAS of ischemic or hemorrhagic stroke, 6,224 individuals (450 subjects with ischemic stroke, 5,774 controls) or 6,179 individuals (261 subjects with ICH, 176 subjects with SAH, 5,742 controls), respectively, were examined. EWASs were performed with the use of Illumina Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip. To compensate for multiple comparisons of allele frequencies with ischemic stroke, ICH, or SAH, we applied a false discovery rate (FDR) of <0.05 for statistical significance of association. The association of allele frequencies of 31,245 single nucleotide polymorphisms (SNPs) that passed quality control to ischemic stroke was examined with Fisher’s exact test, and 31 SNPs were significantly (FDR <0.05) associated with ischemic stroke. The association of allele frequencies of 31,253 or 30,970 SNPs to ICH or SAH, respectively, was examined with Fisher’s exact test, and six or two SNPs were significantly associated with ICH or SAH, respectively. Multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of hypertension and diabetes mellitus revealed that 12 SNPs were significantly [P<0.0004 (0.05/124)] related to ischemic stroke. Similar analysis with adjustment for age, sex, and the prevalence of hypertension revealed that six or two SNPs were significantly [P<0.0016 (0.05/32)] related to ICH or SAH, respectively. After examination of linkage disequilibrium of identified SNPs and results of previous GWASs, we identified HHIPL2, CTNNA3, LOC643770, UTP20, and TRIB3 as susceptibility loci for ischemic stroke, DNTTIP2 and FAM205A as susceptibility loci for ICH, and FAM160A1 and OR52E4 as such loci for SAH. Therefore, to the best of our knowledge, we have newly identified nine genes that confer susceptibility to early-onset ischemic stroke, ICH, or SAH. Determination of genotypes for the SNPs in these genes may prove informative for assessment of the genetic risk for ischemic stroke, ICH, or SAH in Japanese.

Introduction

Stroke is the leading cause of severe disability and a life-threatening condition (1). In 2015, there were 6.3 million stroke deaths worldwide (11.8% of total deaths), making stroke the second leading cause of death behind ischemic heart disease (2). Of all strokes, 87% are ischemic stroke, 10% are intracerebral
hemorrhage (ICH), and 3% are subarachnoid hemorrhage (SAH) in the United States (2). The etiology of common forms of stroke is multifactorial and includes both genetic and environmental factors (2,3). Studies with twins, siblings, and families provided substantial evidence for heritability of stroke (2,4). Given that personalized prevention is important to reduce overall burden of stroke, identification of genetic variants for stroke risk is key both for risk prediction and for potential intervention to avert future cerebrovascular events.

The Trial of ORG 10172 in Acute Stroke Treatment (TOAST) study (5) classified ischemic stroke into five subtypes: i) Large-artery atherosclerosis; ii) cardioembolism; iii) small-vessel occlusion; iv) stroke of other determined etiology; and v) stroke of undetermined etiology. A family history study of 1,000 individuals with ischemic stroke and 800 controls showed that a family history of stroke was a risk factor for both large-vessel atherosclerosis and small-vessel occlusion, especially in cases aged <65 years (6). The heritability of ischemic stroke was estimated to be 40.3% for large-vessel disease, 32.6% for cardioembolic stroke, 16.1% for small-vessel disease, and 37.9% for all ischemic stroke (7). These observations suggest that genetic components play important roles in the pathogenesis of ischemic stroke, in addition to conventional risk factors such as hypertension and diabetes mellitus (2,8,9).

Genome-wide association studies (GWASs) in European ancestry populations identified various genes and loci that confer susceptibility to ischemic stroke (10-17). A recent GWAS identified HDAC9 and chromosome 1p13.2 (near TSPAN2) as susceptibility loci for large-vessel disease, PITX2 and ZFHX3 as loci for cardioembolic stroke, and 12q24 (near ALDH2) as a susceptibility locus for small-vessel disease, indicating that ischemic stroke-related loci are subtype specific (18). A more recent multiancestry meta-analysis of GWASs identified 32 loci including 22 new loci that confer susceptibility to stroke (19).

ICH accounts for a large proportion of severe or fatal cases of stroke, with its most important risk factors being hypertension and advanced age (20). Familial aggregation of ICH cases was demonstrated in a prospective study in North Carolina in the United States, showing that 10% of affected individuals had a family history of ICH (21). Genetic factors may influence, not only the development of ICH, but also the prevalence of risk factors for this condition, such as hypertension (22).

ICH has a substantial genetic component with heritability of deep or lobar ICH being estimated at 34 and 73%, respectively (23). Previous genetic association studies suggested several genes and loci are involved in the predisposition to ICH (24-27). A meta-analysis of GWASs for ICH in European ancestry populations identified chromosome 12q21.1 (near TRHDE) as a susceptibility locus for lobar ICH and 1q22 (near PMF1-SCL25A44) as a locus for non-lobar ICH (28).

SAH is commonly caused by rupture of an aneurysm in an intracranial artery (29). Given that a family history is an important risk factor for the development of intracranial aneurysm, genetic components may play important roles in the development of SAH (30-32). The heritability of SAH was estimated as 41% (33). GWASs have implicated several loci and genes that confer susceptibility to intracranial aneurysm (34-38). A meta-analysis of GWASs identified 19 genetic variants associated with intracranial aneurysm (39).

Although several single nucleotide polymorphisms (SNPs) have been found to be significantly associated with ischemic stroke (40,41) or intracranial aneurysm (42) in Japanese subjects, genetic variants that confer susceptibility to ischemic stroke, ICH, or SAH in Japanese remain to be identified definitively.

In a family and twin study of ischemic stroke, heritability was higher in early-onset than late-onset individuals with this condition (6,43,44), suggesting that early-onset ischemic stroke has a strong genetic component. Similar to ischemic stroke, early-onset ICH (45) and SAH (46) were shown to have strong genetic components. Given that a genetic contribution may be greater in early-onset forms than in late-onset forms of ischemic stroke, ICH, and SAH, statistical power of the genetic association study may be increased by focusing on early-onset subjects with diseases (6). We performed exome-wide association studies (EWASs) with the use of human exome array-based genotyping methods to identify genetic variants that confer susceptibility to ischemic stroke, ICH, or SAH in Japanese individuals. To increase the statistical power of EWASs, we examined early-onset subjects with these conditions.

Materials and methods

Study subjects. In our previous study (47), the median age of subjects with ischemic stroke, ICH, or SAH was 74, 71, or 60 years, respectively. We thus defined patients aged ≤65 years as early-onset cases in the present study. A total of 6,649 individuals aged ≤65 years were examined. For the EWAS of ischemic stroke, 6,224 individuals (450 subjects with ischemic stroke, and 5,774 controls) were examined. For the EWAS of hemorrhagic stroke, 6,179 individuals (261 subjects with ICH, 176 subjects with SAH, and 5,742 controls) were examined. Most control individuals were the same for the studies of ischemic and hemorrhagic stroke. The subjects were recruited from individuals who visited outpatient clinics of or were admitted to participating hospitals in Japan (Gifu Prefectural Tajimi Hospital, Tajimi; Gifu Prefectural General Medical Center, Gifu; Japanese Red Cross Nagoya First Hospital, Nagoya; Northern Mie Medical Center Inabe General Hospital, Inabe; Hirosaki University Hospital and Hirosaki Stroke and Rehabilitation Center, Hirosaki) because of various symptoms or for an annual health checkup between October 2002 and March 2014; or who were community-dwelling individuals recruited to a population-based cohort study in Inabe between March 2010 and September 2014 (48).

The diagnosis of ischemic stroke, ICH, or SAH was based on the occurrence of a new and abrupt focal neurological deficit, with neurological symptoms and signs persisting for >24 h, and it was confirmed by positive findings in computed tomography or magnetic resonance imaging (or both) of the head. The type of stroke was determined according to the Classification of Cerebrovascular Diseases III (49). Given that susceptibility loci for ischemic stroke are subtype-specific (18), we examined subjects with atherothrombotic cerebral infarction (large-vessel disease).

For the study of ischemic stroke, subjects with cardioembolic stroke, lacunar infarction alone, transient ischemic attack, hemorrhagic stroke, cerebrovascular...
malformations, moyamoya disease, cerebral venous sinus thrombosis, brain tumors, or traumatic cerebrovascular diseases were excluded from enrollment. For the studies of hemorrhagic stroke, individuals with ischemic stroke, lacunar infarction, transient ischemic attack, intracranial hemorrhage resulting from cerebrovascular malformations, moyamoya disease, cerebral venous sinus thrombosis, brain tumors, traumatic cerebrovascular diseases, or subdural hematoma were excluded. The control individuals had no history of ischemic or hemorrhagic stroke; of aortic, coronary, or peripheral artery disease; or of other thrombotic, embolic, or hemorrhagic disorders. Individuals with unruptured intracranial aneurysm were also excluded from controls. The absence of stroke history was evaluated with a detailed questionnaire and was confirmed by the absence of a history of neurological deficits.

EWASs. Venous blood was collected into tubes containing 50 mmol/l ethylenediaminetetraacetic acid (disodium salt), peripheral blood leukocytes were isolated, and genomic DNA was extracted from these cells either with a DNA extraction kit (Genomix, Talent Srl, Trieste, Italy) or SMITEST EX-R&D (Medical & Biological Laboratories, Co., Ltd., Nagoya, Japan). EWASs were performed with the use of a Human Exome-12 v1.2 DNA Analysis BeadChip or Infinium Exome-24 v1.0 BeadChip (Illumina, San Diego, CA, USA), both of which include putative functional exonic variants selected from ~12,000 individual exome and whole-genome sequences. The exonic content of ~244,000 SNPs represents diverse populations including European, African, Chinese, and Hispanic individuals (50). SNPs contained in only one of the exome arrays (~2.6% of all SNPs) were excluded from analysis. We performed quality control (51) as follows: i) Genotyping data with a call rate of <97% were discarded, with the mean call rate for the remaining data being 99.9%. ii) Sex specification was checked for all samples, and those for which sex phenotype in the clinical records was inconsistent with genetic sex were discarded. iii) Duplicated samples and cryptic relatedness were checked by calculation of identity by descent; all pairs of DNA samples showing identity by descent of >0.1875 were inspected, and one sample from each pair was excluded. iv) Heterozygosity of SNPs was calculated for all samples, with those showing extremely low or high heterozygosity (>3 standard deviations from the mean) being discarded. v) SNPs in sex chromosomes or in mitochondrial DNA were excluded from the analysis, as were non-polymorphic SNPs or SNPs with a minor allele frequency of <1.0%. vi) SNPs whose genotype distributions deviated significantly (P<0.01) from Hardy-Weinberg equilibrium in control individuals were discarded. vii) Genotype data were examined for population stratification by principal components analysis (52), and population outliers were excluded from the analysis. Totals of 31,245, 31,253, or 30,970 SNPs that passed quality control for the study of ischemic stroke, ICH, or SAH, respectively, were subjected to analysis.

Statistical analysis. For analysis of characteristics of the study subjects, quantitative data were presented as means ± SD, and were compared between subjects with ischemic stroke, ICH, or SAH and controls with the unpaired Student's t-test. Categorical data were compared between two groups with Pearson's Chi-square test. Allele frequencies were estimated by the gene counting method, and Fisher's exact test was applied to identify departure from Hardy-Weinberg equilibrium. Allele frequencies of SNPs were compared between subjects with ischemic stroke, ICH, or SAH, and corresponding controls with Fisher's exact test. To compensate for multiple comparisons of allele frequencies with ischemic stroke, ICH, or SAH, we applied a false discovery rate (FDR) (53) for statistical significance of association. The significance level was set at a FDR of <0.05 for each EWAS. The inflation factor (λ) was 1.06 for ischemic stroke, 1.10 for ICH, and 1.11 for SAH. Multivariable logistic regression analysis was performed with ischemic stroke as a dependent variable and independent variables including age, sex (0, woman; 1, man), the prevalence of hypertension and diabetes mellitus (0, no history of these conditions; 1, positive history), and genotype of each SNP. A similar analysis was performed with ICH or SAH as a dependent variable and independent variables including age, sex, the prevalence of hypertension, and genotype of each SNP. Genotypes of each SNP were assessed according to dominant (0, AA; 1, AB + BB (A, major allele; B, minor allele)), recessive (0, AA + AB; 1, BB), and additive genetic models, and the P-value, odds ratio, and 95% confidence interval were calculated. Additive models comprised additive 1 (0, AA; 1, AB; 0, BB) and additive 2 (0, AA; 0, AB; 1, BB) scenarios, which were analyzed simultaneously with a single statistical model. The association of genotypes of SNPs to intermediate phenotypes was examined with Pearson's Chi-square test and P-values were shown. Bonferroni's correction was applied to other statistical analyses as indicated. Statistical tests were performed with JMP Genomics version 9.0 software (SAS Institute, Cary, NC, USA).

Results

Characteristics of subjects. The characteristics of the 6,224 subjects enrolled in the ischemic stroke study are shown in Table I. Age, the frequency of men, and the prevalence of hypertension, diabetes mellitus, dyslipidemia, and chronic kidney disease as well as systolic and diastolic blood pressure (BP), fasting plasma glucose (FPG) level, blood glycosylated hemoglobin (hemoglobin A1c) content, and serum concentrations of triglycerides were greater, whereas serum concentration of high density lipoprotein (HDL)-cholesterol and estimated glomerular filtration rate (eGFR) were lower, in subjects with ischemic stroke than in controls.

The characteristics of the subjects enrolled in the hemorrhagic stroke study are shown in Table II. Age, the frequency of men, and the prevalence of hypertension, diabetes mellitus, and chronic kidney disease as well as systolic and diastolic BP, FPG level, blood hemoglobin A1c content, and serum concentrations of triglycerides were greater, whereas serum concentrations of HDL-cholesterol and low density lipoprotein (LDL)-cholesterol were lower, in subjects with ICH than in controls. The prevalence of hypertension, diabetes mellitus, and chronic kidney disease as well as systolic and diastolic BP, FPG level, and serum concentrations of triglycerides were greater, whereas the prevalence of dyslipidemia and the serum
concentration of HDL-cholesterol were lower, in subjects with SAH than in controls.

**EWAS for ischemic stroke, ICH, or SAH.** We examined the association of allele frequencies of 31,245 SNPs that passed quality control to ischemic stroke with the use of Fisher's exact test, and detected that 31 SNPs were significantly (FDR <0.05) associated with ischemic stroke (Table III). The relation of allele frequencies of 31,253 or 30,970 SNPs to ICH or SAH, respectively (Table IV).

**Multivariable logistic regression analysis of the association of SNPs to ischemic stroke, ICH, or SAH.** The association of the 31 identified SNPs in the EWAS of ischemic stroke was further examined by multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of hypertension and diabetes mellitus (Table V). The 12 SNPs were significantly [P<0.0004 (0.05/124) in at least one genetic model] related to ischemic stroke. The association of the six or two SNPs identified in the EWAS for ICH or SAH, respectively, to these conditions was examined by multivariable logistic regression analysis with adjustment for age, sex, and the prevalence of hypertension (Table VI). The SNPs were significantly [P<0.0016 (0.05/32)] related to ICH or SAH.

**Table I. Characteristics of subjects with ischemic stroke and control individuals.**

| Characteristic                              | Control | Ischemic stroke | P-value   |
|--------------------------------------------|---------|----------------|-----------|
| No. of subjects                            | 5,774   | 450            | <0.0001   |
| Age (years)                                | 50.6±10.2 | 56.7±7.1     | <0.0001   |
| Sex (men/women, %)                         | 52.1/47.9 | 67.8/32.2    | <0.0001   |
| Smoking (%)                                | 42.5    | 35.6          | 0.0093    |
| Obesity (%)                                | 31.0    | 33.3          | 0.3484    |
| Body mass index (kg/m²)                    | 23.2±3.5 | 23.9±3.8      | 0.0002    |
| Hypertension (%)                           | 31.7    | 72.5          | <0.0001   |
| Systolic BP (mmHg)                         | 121±18  | 149±30        | <0.0001   |
| Diastolic BP (mmHg)                        | 75±13   | 86±17         | <0.0001   |
| Diabetes mellitus (%)                      | 12.7    | 47.5          | <0.0001   |
| Fasting plasma glucose (mmol/l)            | 5.66±1.78 | 7.16±3.00    | <0.0001   |
| Blood hemoglobin A₁c (%)                   | 5.72±0.96 | 6.52±1.66    | <0.0001   |
| Dyslipidemia (%)                           | 56.9    | 66.3          | 0.0001    |
| Serum triglycerides (mmol/l)               | 1.32±0.98 | 1.67±1.03    | <0.0001   |
| Serum HDL-cholesterol (mmol/l)             | 1.65±0.45 | 1.30±0.42    | <0.0001   |
| Serum LDL-cholesterol (mmol/l)             | 3.18±0.83 | 3.13±0.93    | 0.5012    |
| Chronic kidney disease (%)                 | 10.3    | 31.2          | <0.0001   |
| Serum creatinine (µmol/l)                  | 69.8±61.0 | 88.4±120.2   | 0.0041    |
| eGFR (ml min⁻¹ 1.73 m⁻²)                   | 78.7±17.1 | 71.1±23.7    | <0.0001   |
| Hyperuricemia (%)                          | 15.2    | 19.1          | 0.0290    |
| Serum uric acid (µmol/l)                   | 321±89  | 337±96        | 0.0027    |

Quantitative data are means ± standard deviations and were compared between subjects with ischemic stroke and controls with the unpaired Student’s t-test. Categorical data were compared between two groups with Pearson’s Chi-square test. Based on Bonferroni’s correction, a P-value of <0.0025 (0.05/20) was considered statistically significant. BP, blood pressure; HDL, high density lipoprotein; LDL, low density lipoprotein; eGFR, estimated glomerular filtration rate.

**Relationship of SNPs associated with ischemic stroke, ICH, or SAH to intermediate phenotypes.** We examined the relationship of the 12 SNPs associated with ischemic stroke to intermediate phenotypes of this condition (including hypertension, diabetes mellitus, hypertriglyceridemia, hypo-HDL-cholesterolemia, hyper-LDL-cholesterolemia, chronic kidney disease, obesity, and hyperuricemia) with the use of Pearson's Chi-square test. None of the SNPs was related to intermediate phenotypes (Table VII). The relationship of six or two SNPs associated with ICH or SAH, respectively, to intermediate phenotypes of these conditions was also examined. The rs12229654 at chromosome 12q24.1, rs671 of ALDH2, and rs11066015 of ACAD10 associated with ICH were significantly related to hypertension, hyper-LDL-cholesterolemia, and hyperuricemia, whereas none of SNPs associated with SAH was related to intermediate phenotypes (Table VIII).

**Linkage disequilibrium analyses.** We examined linkage disequilibrium (LD) among SNPs associated with ischemic stroke or ICH. For the ischemic stroke study, rs3130688 at chromosome 6p21.3 and rs2308557 of HLA-C were in complete LD [square of the correlation coefficient (r²), 1.000], whereas rs3130981 and rs3130984 of CDSN were not in LD. For the ICH study, there was significant LD (r², 0.650 to 0.995) among rs12229654 at 12q24.1, rs11066015 of ACAD10, and rs671 of ALDH2 (data not shown).
Association of genes, chromosomal loci, and SNPs identified in the present study to phenotypes reported by previously GWASs. In the ischemic stroke study, CDK18 was shown to be related to type 1 diabetes mellitus (T1DM); CDSN to T1DM and serum concentrations of triglycerides; HLA-C to T1DM and serum concentrations of triglycerides and LDL-cholesterol; NYNRIN to serum concentration of LDL-cholesterol; and GOSR2 to systolic BP. The remaining five genes (HHIPL2, CTNNA3, LOC643770, UTP20, TRIB3) were not found to be related to ischemic stroke or other cerebrovascular disease-related phenotypes (Table IX). In the study of hemorrhagic stroke, SVEP1 was shown to be related to coronary artery disease (CAD); chromosome 12q24.1 to serum HDL-cholesterol level; ACD10 to CAD, serum LDL-cholesterol level, T1DM, and diastolic BP; and ALDH2 to CAD, myocardial infarction (MI), serum concentrations of HDL-cholesterol and LDL-cholesterol, T1DM, and systolic and diastolic BP. The remaining four genes (DNTTIP2, FAM205A, FAM160A1, OR52E4) were not related to ICH, SAH, or other cerebrovascular disease-related phenotypes (Table X).

Discussion

Given that stroke is a serious condition and is a global public health problem (1,2,20,29), identification of genetic variants that confer susceptibility to ischemic stroke, ICH, and SAH is clinically important to prevent these conditions. In the present study, we performed EWASs for ischemic stroke, ICH, and SAH in early-onset subjects who may have greater genetic components compared with late-onset individuals.

In the study of ischemic stroke, among 10 genes and one chromosomal locus identified, CDK18, CDSN, HLA-C, NYNRIN and GOSR2 were shown to be related to T1DM (55-56), serum concentrations of triglycerides or LDL-cholesterol (57), or systolic BP (58,59) which are risk factors for ischemic stroke. Although rs3130688 at chromosomal 6p21.3 was not related to cerebrovascular phenotype, this region was previously related to CAD (60). We thus identified HHIPL2, CTNNA3, LOC643770, UTP20 and TRIB3 as novel susceptibility loci for ischemic stroke. The five genes associated with ischemic stroke were not related to intermediate phenotypes, although the relation of UTP20 to chronic kidney disease was borderline significance. The underline molecular mechanisms of the association of these genes with ischemic stroke remain unclear.

In the study of hemorrhagic stroke, of the seven genes and one chromosomal locus identified, SVEP1, ACD10 and ALDH2 were shown to be related to CAD or MI (60-62). ACD10 and ALDH2 were previously related to systolic or diastolic BP (58,59); and these genes as well as chromosome 12q24.1 were previously related to the serum concentrations.
Table III. The 31 SNPs significantly (FDR <0.05) associated with ischemic stroke in the exome-wide association study.

| Gene       | SNP            | Nucleotide substitution | Amino acid substitution | Chromosome | Position     | MAF (%) | Allele OR (allele frequency) | P-value (allele frequency) | FDR (allele frequency) |
|------------|----------------|-------------------------|-------------------------|------------|--------------|---------|-----------------------------|--------------------------|------------------------|
| PLCB2     | rs200787930    | C/T                     | E1106K                  | 15         | 40289298     | 1.2     | 0.07                        | 3.81x10^{-9}            | 6.48x10^{6}            |
| VPS33B    | rs199921354    | C/T                     | R80Q                    | 15         | 91013841     | 1.2     | 0.07                        | 5.62x10^{-9}            | 8.83x10^{6}            |
| CXCL5     | rs188378669    | G/T                     | E31*                    | 4          | 73741568     | 1.2     | 0.07                        | 5.71x10^{-9}            | 8.83x10^{6}            |
| MARCHI1   | rs61734696     | G/T                     | Q137K                   | 4          | 164197303    | 1.2     | 0.07                        | 5.89x10^{-9}            | 8.83x10^{6}            |
| ADGRL3    | rs192210727    | G/T                     | R580I                   | 4          | 61909615     | 1.3     | 0.07                        | 5.85x10^{-9}            | 8.83x10^{6}            |
| TMOD4     | rs115287176    | G/A                     | R277W                   | 1          | 151170961    | 1.2     | 0.08                        | 8.35x10^{-9}            | 1.22x10^{5}            |
| COL6A3    | rs146092501    | G/T                     | E31*                    | 4          | 73741568     | 1.2     | 0.08                        | 1.25x10^{-8}            | 1.72x10^{5}            |
| ZNF77     | rs146879198    | G/A                     | R340*                   | 19         | 2934109      | 1.2     | 0.08                        | 1.25x10^{-8}            | 1.72x10^{5}            |
| NYNRIN    | rs149771079    | G/A                     | D467N                   | 14         | 24409193     | 1.2     | 3.33                        | 5.03x10^{-4}            | 6.23x10^{4}            |
| GOSR2     | rs1052586      | T/C                     | E1106K                  | 17         | 46941097     | 48.7    | 0.70                        | 2.01x10^{-6}            | 0.0020                 |
|           | rs12662501     | C/T                     | E1106K                  | 6          | 31223073     | 7.3     | 1.68                        | 1.14x10^{-5}            | 0.0104                 |
|           | rs17435433     | T/C                     | E1106K                  | 2          | 88210097     | 25.8    | 1.39                        | 1.24x10^{-5}            | 0.0111                 |
|           | rs745967       | T/G                     | E1106K                  | 6          | 31346466     | 15.3    | 1.49                        | 1.85x10^{-5}            | 0.0153                 |
| HLA-C     | rs2308557      | G/A                     | S101N                   | 6          | 31271640     | 1.2     | 1.62                        | 2.54x10^{-3}            | 0.0205                 |
|           | rs3130688      | T/C                     | S101N                   | 6          | 31242439     | 18.6    | 1.43                        | 2.77x10^{-3}            | 0.0215                 |
| HHIPL2    | rs3748665      | C/T                     | S101N                   | 1          | 222540279    | 7.4     | 0.51                        | 2.88x10^{-3}            | 0.0218                 |
| MUC22     | rs11756038     | A/G                     | T1376A                  | 6          | 31029557     | 5.0     | 1.73                        | 5.41x10^{-3}            | 0.0392                 |
| LOC643770 | rs829881       | C/A                     | T1376A                  | 12         | 98487450     | 37.4    | 1.33                        | 6.09x10^{-3}            | 0.0435                 |
| TRIB3     | rs2295490      | A/G                     | Q84R                    | 20         | 388261       | 23.0    | 1.37                        | 6.35x10^{-5}            | 0.0449                 |
| CDSN      | rs3130984      | C/T                     | S143N                   | 6          | 31117187     | 13.4    | 1.47                        | 6.49x10^{-5}            | 0.0449                 |
| HLA-DQB1  | rs1130375      | C/G                     | A45G                    | 6          | 32665043     | 28.3    | 0.73                        | 6.49x10^{-5}            | 0.0449                 |
| CTNNA3    | rs10997469     | C/T                     | R1376A                  | 10         | 66986527     | 26.1    | 1.35                        | 7.04x10^{-3}            | 0.0477                 |
| C6orf15   | rs2233977      | T/C                     | S143N                   | 6          | 31100249     | 44.0    | 0.76                        | 7.44x10^{-3}            | 0.0492                 |
| CDSN      | rs3130981      | C/T                     | D527N                   | 6          | 31116036     | 13.6    | 1.46                        | 7.48x10^{-3}            | 0.0492                 |
| DDAH1     | rs12742253     | T/G                     | D527N                   | 1          | 85505292     | 44.9    | 0.76                        | 8.45x10^{-3}            | 0.0499                 |
| HLA-DQB1  | rs1130370      | A/C                     | Y69D                    | 6          | 32664972     | 18.6    | 0.69                        | 8.19x10^{-5}            | 0.0499                 |
| CDK18     | rs77571454     | G/A                     | G466E                   | 1          | 205531350    | 5.1     | 1.72                        | 8.4x10^{-3}             | 0.0499                 |
| CNTNNA3   | rs1925608      | A/C                     | D527N                   | 10         | 66990654     | 32.2    | 1.33                        | 8.35x10^{-3}            | 0.0499                 |
| UTP20     | rs117417637    | G/A                     | R1520H                  | 12         | 101344704    | 1.8     | 2.33                        | 8.07x10^{-3}            | 0.0499                 |

Allele frequencies were analyzed with Fisher's exact test. *Major allele/minor allele. SNP, single nucleotide polymorphism; FDR, false discovery rate; MAF, minor allele frequency; OR, odds ratio.
Table IV. The eight SNPs significantly (FDR <0.05) associated with intracerebral hemorrhage or subarachnoid hemorrhage in the exome-wide association study.

| Gene      | SNP          | Nucleotide substitution | Amino acid substitution | Chromosome | Position | MAF (%) | Allele OR (allele frequency) | P-value | FDR (allele frequency) |
|-----------|--------------|-------------------------|-------------------------|------------|----------|---------|-------------------------------|---------|------------------------|
| **Intracerebral hemorrhage** |             |                         |                         |            |          |         |                               |         |                        |
| FAM205A   | rs12229654   | T/G                     |                         | 12         | 110976657| 22.5    | 0.59                          | 7.66x10^-6| 0.0093                  |
| GOSR2     | rs13739881   | A/C                     | I999S                   | 9          | 34724244 | 36.9    | 0.66                          | 1.53x10^-5| 0.0178                  |
| SVEP1     | rs7030192    | G/A                     | A2750V                  | 9          | 110407351| 40.9    | 1.47                          | 1.71x10^-5| 0.0192                  |
| DNTTIP2   | rs3747965    | T/G                     | D309E                   | 1          | 93877008 | 42.5    | 1.47                          | 2.86x10^-5| 0.0316                  |
| ALDH2     | rs7671       | G/A                     | E504K                   | 12         | 111803962| 27.6    | 0.65                          | 4.76x10^-5| 0.0483                  |
| ACAD10    | rs11066015   | G/A                     |                         | 12         | 111730205| 27.5    | 0.65                          | 4.76x10^-5| 0.0483                  |
| **Subarachnoid hemorrhage** |             |                         |                         |            |          |         |                               |         |                        |
| OR52E4    | rs1182382    | T/G                     | F227L                   | 11         | 5884973  | 36.6    | 1.82                          | 2.48x10^-6| 0.0063                  |
| FAM160A1  | rs270982     | C/T                     |                         | 4          | 151434116| 33.1    | 0.57                          | 5.96x10^-6| 0.0145                  |

Allele frequencies were analyzed with Fisher's exact test. *Major allele/minor allele. SNP, single nucleotide polymorphism; FDR, false discovery rate; MAF, minor allele frequency; OR, odds ratio.

Table V. Association of SNPs to ischemic stroke as determined by multivariable logistic regression analysis.

| Gene      | SNP          | Dominant | P-value | OR  | 95% CI      | Recessive | P-value | OR  | 95% CI      | Additive 1 | P-value | OR  | 95% CI      | Additive 2 | P-value | OR  | 95% CI      |
|-----------|--------------|----------|---------|-----|-------------|-----------|---------|-----|-------------|-----------|---------|-----|-------------|-----------|---------|-----|-------------|
| NYNRIN    | rs149771079  | G/A      | <0.0001 | 3.21| 2.03-5.07   |           |         |     |             |           |         |     |             |           |         |     |             |
| GOSR2     | rs1052586    | T/C      | 0.0077  | 0.71| 0.55-0.91   |           |         |     |             |           |         |     |             |           |         |     |             |
| HLA-C     | rs2308557    | G/A      | 0.0004  | 1.61| 1.24-2.09   | 0.0409    | 0.47   | 0.34-0.64 |           |         |     |             |           |         |     |             |
| HHIIPL2   | rs3748665    | C/T      | 0.0003  | 0.50| 0.34-0.73   | 0.4082    |         |     |             |           |         |     |             |           |         |     |             |
| LOC643770 | rs829881     | C/A      | 0.0004  | 1.51| 1.20-1.90   | <0.0001   | 1.71   | 1.31-2.24 |           |         |     |             |           |         |     |             |
| TRIB3     | rs2295490    | A/G      | <0.0001 | 1.53| 1.24-1.90   | 0.0021    | 1.88   | 1.26-2.81 |           |         |     |             |           |         |     |             |
| CDSN      | rs3130984    | C/T      | <0.0001 | 1.62| 1.28-2.04   | 0.9814    |         |     |             | <0.0001   | 1.65   | 1.30-2.09 |           |         |     |             |
| CDSN      | rs3130984    | C/T      | <0.0001 | 1.61| 1.28-2.03   | 0.9850    |         |     |             | <0.0001   | 1.64   | 1.30-2.08 |           |         |     |             |
| CDK18     | rs77571454   | G/A      | 0.0001  | 1.86| 1.36-2.55   | 0.2692    |         |     |             | <0.0001   | 1.90   | 1.38-2.61 |           |         |     |             |
| CTNNA3    | rs1925608    | A/C      | 0.0080  | 1.34| 1.08-1.67   | 0.0018    | 1.64   | 1.20-2.24 |           |         |     |             |           |         |     |             |
| UTP20     | rs117417637  | G/A      | <0.0001 | 2.72| 1.76-4.20   | 0.5873    |         |     |             | <0.0001   | 2.76   | 1.79-4.26 |           |         |     |             |

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension and diabetes mellitus. Based on Bonferroni's correction; a P-value of <0.0004 (0.05/124) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.
Table VI. Relation of SNPs to intracerebral hemorrhage or subarachnoid hemorrhage as determined by multivariable logistic regression analysis.

| Gene   | SNP   | Dominant |  |  | Recessive |  |  | Additive 1 |  |  | Additive 2 |  |  |
|--------|-------|----------|---|---|-----------|---|---|------------|---|---|------------|---|---|
|        |       | P-value  | OR | 95% CI | P-value  | OR | 95% CI | P-value  | OR | 95% CI | P-value  | OR | 95% CI |
| Intracerebral hemorrhage | | | | | | | | | | | | | |
| rs12229654 | T/G | 0.0002 | 0.58 | 0.44-0.77 | | | | | | | | | |
| rs3739881 | A/C | 0.0008 | 0.64 | 0.50-0.83 | | | | | | | | | |
| rs7030192 | G/A | 0.0003 | 1.73 | 1.28-2.34 | | | | | | | | | |
| rs3747965 | T/G | 0.0063 | 1.52 | 1.13-2.05 | | | | | | | | | |
| rs671 | G/A | 0.0004 | 0.61 | 0.47-0.80 | | | | | | | | | |
| rs11066015 | G/A | 0.0004 | 0.61 | 0.47-0.81 | | | | | | | | | |
| rs11823828 | T/G | 0.0349 | 1.48 | 1.03-2.14 | | | | | | | | | |
| rs2709828 | C/T | 0.0002 | 0.55 | 0.41-0.75 | | | | | | | | | |
| Subarachnoid hemorrhage | | | | | | | | | | | | | |
| OR52E4 | rs11823828 | G/A | 0.0001 | 3.12 | 2.14-4.54 | | | | | | | | |
| rs2709828 | C/T | 0.0002 | 0.55 | 0.41-0.75 | | | | | | | | | |

Multivariable logistic regression analysis was performed with adjustment for age, sex, and the prevalence of hypertension. Based on Bonferroni’s correction, a P-value of <0.0006 (0.05/32) was considered statistically significant. SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.

Table VII. Relation of SNPs associated with ischemic stroke to intermediate phenotypes.

| Gene   | SNP   | Hypertension | DM | Hyper-TG | Hypo-HDL | Hyper-LDL | CKD | Obesity | Hyperuricemia |
|--------|-------|--------------|----|----------|----------|-----------|-----|---------|---------------|
| NYNRIN | rs149771079 | G/A | 0.0054 | 0.0686 | 0.2117 | 0.6340 | 0.9385 | 0.6942 | 0.9354 | 0.2993 |
| GOSR2  | rs1052586   | T/C | 0.7587 | 0.7483 | 0.2289 | 0.7387 | 0.2092 | 0.3107 | 0.1309 | 0.8628 |
| HLA-C  | rs2308557   | G/A | 0.0188 | 0.1881 | 0.4974 | 0.1409 | 0.7632 | 0.5904 | 0.4666 | 0.0329 |
| rs3130688 | T/C | 0.3913 | 0.4724 | 0.0746 | 0.4322 | 0.0165 | 0.5385 | 0.4440 | 0.7564 |
| HHIIPL2 | rs3748665 | C/T | 0.9811 | 0.7782 | 0.6295 | 0.4509 | 0.3465 | 0.0781 | 0.2633 | 0.4430 |
| LOC643770 | rs829881 | C/A | 0.4804 | 0.1812 | 0.2885 | 0.5240 | 0.7785 | 0.1223 | 0.1292 | 0.5389 |
| TRIB3  | rs2295490   | A/G | 0.6434 | 0.6909 | 0.5038 | 0.1135 | 0.1603 | 0.0762 | 0.2842 | 0.2079 |
| CDSN   | rs3130984   | C/T | 0.4946 | 0.7936 | 0.4541 | 0.3164 | 0.0451 | 0.8039 | 0.9544 | 0.0920 |
| rs3130981 | C/T | 0.4921 | 0.8212 | 0.4463 | 0.3344 | 0.0459 | 0.8039 | 0.9541 | 0.0923 |
| CDTK18 | rs77571454  | G/A | 0.5132 | 0.7996 | 0.7437 | 0.7177 | 0.9208 | 0.5647 | 0.2642 | 0.3218 |
| CTNNA3 | rs1925608   | A/C | 0.5025 | 0.8597 | 0.2367 | 0.8708 | 0.1496 | 0.7296 | 0.7227 | 0.4908 |
| UTP20  | rs117417637 | G/A | 0.2032 | 0.9101 | 0.5860 | 0.1956 | 0.0396 | 0.0006 | 0.1973 | 0.4511 |

Data are P-values. The relationship of genotypes of each SNP to intermediate phenotypes was examined with Pearson’s Chi-square test. SNP, single nucleotide polymorphism; DM, diabetes mellitus; hyper-TG, hypertriglyceridemia; hypo-HDL, hypo-HDL-cholesterolemia; hyper-LDL, hyper-LDL-cholesterolemia; CKD, chronic kidney disease. Based on Bonferroni’s correction; a P-value of <0.0005 (0.05/96) was considered statistically significant.
These phenotypes are related to cerebrovascular disease. We thus identified DNTTIP2 and FAM205A as new susceptibility loci for ICH, and FAM160A1 and OR52E4 as loci for SAH. Given that the four genes associated with ICH or SAH were not related to intermediate phenotypes, the functional relevance of the association of these genes with ICH or SAH remains to be elucidated.

We previously showed that four, six, or three SNPs were associated with ischemic stroke (P<0.01), ICH (P<0.05), or SAH (P<0.05), respectively, as determined by multivariable logistic regression analysis with adjustment for covariates after the initial EWAS screening among both early- and late-onset subjects with these conditions (47). The relationship of four SNPs to ischemic stroke was not replicated (P<0.05) in the present study. The relation of one of six SNPs [rs138533962 (P=0.0019)] to ICH was replicated in the present study. The association of one of three SNPs [rs117564807 (P=0.0454)] to SAH was replicated in the present study. The results suggest that genetic variants that confer susceptibility to ischemic stroke, ICH, or SAH may differ, in part, between early-onset and late-onset subjects with these conditions.

There are several limitations to our study: i) Given that the results were not replicated, their validation will be necessary in independent study populations or in other ethnic groups. ii) It is possible that SNPs identified in the present study are in LD with other genetic variants in the same gene or in other nearby genes that are actually responsible for the development of ischemic stroke, ICH, or SAH. iii) The functional relevance of identified SNPs to the pathogenesis of ischemic stroke, ICH, or SAH remains to be elucidated.

In conclusion, we have newly identified five (HHIPL2, CTNNA3, LOC643770, UTP20, TRIB3), two (DNTTIP2, FAM205A), or two (FAM160A1, OR52E4) genes as susceptibility loci for early-onset ischemic stroke, ICH, or SAH, respectively. Determination of genotypes for the SNPs in these genes may prove informative for assessment of the genetic risk for ischemic stroke, ICH, or SAH in Japanese subjects.

Acknowledgements

Not applicable.

Funding

This study was supported by CREST (JPMJCR1302), Japan Science and Technology Agency (to YYam, JS and IT).

Availability of data and materials

All data underlying the findings described in the article are available upon request from the corresponding author.

Authors’ contributions

YYam contributed to conception and design of the study; to acquisition, analysis, and interpretation of the data; and to drafting of the manuscript. KK, MO, HH and TF each contribu-
Table IX. Relationship of genes, chromosomal loci, and SNPs associated with ischemic stroke in the present study to previously reported cerebrovascular disease-related phenotypes.

| Gene/chr. locus | SNP     | Chr. | Position     | Previously reported phenotypes                                      |
|-----------------|---------|------|--------------|--------------------------------------------------------------------|
| CDK18           | rs77571454 | 1    | 205531350    | Type 1 diabetes (21980299)                                         |
| HHIP2           | rs3748665 | 1    | 222540279    | None                                                               |
| CDSN            | rs3130981 | 6    | 31116036     | Type 1 diabetes (17554300), triglycerides (20686565)              |
|                 | rs3130984 | 6    | 31171187     |                                                                     |
| 6p21.3          | rs3130688 | 6    | 31242439     | None                                                               |
| HLA-C           | rs2308557 | 6    | 31271640     | Type 1 diabetes (17632545), total cholesterol (20686565), triglycerides (20686565), LDL-cholesterol (20686565) |
| CTNNA3          | rs1925608 | 10   | 66990654     | None                                                               |
| LOC643770       | rs829881  | 12   | 98487450     | None                                                               |
| UTP20           | rs117417637 | 12  | 101344704    | None                                                               |
| NYNRIN          | rs149771079 | 14 | 24409193     | LDL-cholesterol (20686565), total cholesterol (20686565)           |
| GOSR2           | rs1052586 | 17   | 46941097     | Systolic blood pressure (21909110, 21909115)                       |
| TRIB3           | rs2295490 | 20   | 388261       | None                                                               |

Data were obtained from genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (https://grasp.nhlbi.nih.gov/Search.aspx) with a P-value of <1.0x10^-6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome; LDL, low density lipoprotein.

Table X. Relationship of genes and SNPs associated with intracerebral hemorrhage or subarachnoid hemorrhage in the present study to previously reported cerebrovascular disease-related phenotypes.

| Gene/chr. locus | SNP     | Chr. | Position     | Previously reported phenotypes                                      |
|-----------------|---------|------|--------------|--------------------------------------------------------------------|
| Intracerebral hemorrhage |          |      |              |                                                                    |
| DNTTIP2         | rs3747965 | 1    | 93877008     | None                                                               |
| FAM205A         | rs3739881 | 9    | 34724244     | None                                                               |
| SVEP1           | rs7030192 | 9    | 110407351    | Coronary artery disease (23364394)                                 |
| 12q24.1         | rs12229654 | 12  | 110976657    | HDL-cholesterol (21909109)                                        |
| ACAD10          | rs11066015 | 12  | 111730205    | Coronary artery disease (23364394, 23202125), LDL-cholesterol (20686565), type 1 diabetes (17554300), diastolic blood pressure (21909115) |
| ALDH2           | rs671    | 12   | 111803962    | HDL-cholesterol (21572416, 21372407), myocardial infarction (21971053), coronary artery disease (21971053, 21572416, 23202125), diastolic blood pressure (21572416, 21909115), systolic blood pressure (21572416), LDL-cholesterol (21572416, 20686565), type 1 diabetes (17554300) |

Subarachnoid hemorrhage |          |      |              |                                                                    |
| FAM160A1         | rs2709828 | 4    | 151434116    | None                                                               |
| OR52E4           | rs11823828 | 11  | 5884973      | None                                                               |

Data were obtained from genome-wide repository of associations between SNPs and phenotypes (GRASP) search database (https://grasp.nhlbi.nih.gov/Search.aspx) with a P-value of <1.0x10^-6. Numbers in parentheses are PubMed IDs. SNP, single nucleotide polymorphism; Chr., chromosome; HDL, high density lipoprotein; LDL, low density lipoprotein.

Ethics approval and consent to participate

The study protocol complied with the Declaration of Helsinki.
and was approved by the Committees on the Ethics of Human Research of Mie University Graduate School of Medicine, Hiroasaki University Graduate School of Medicine, and participating hospitals (Gifu Prefectural Tajimi Hospital, Gifu Prefectural General Medical Center, Japanese Red Cross Nagoya First Hospital, Northern Mie Medical Center Inabe General Hospital, and Hiroasaki Stroke and Rehabilitation Center). Written informed consent was obtained from all subjects.

Consent for publication
All authors approved submission of the final version of the article for publication.

Competing interests
The authors declare that they have no competing interests.

References
1. Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, et al: Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group: Global and regional burden of stroke during 1990-2010: Findings from the Global Burden of Disease Study 2010. Lancet 383: 245-254, 2014.
2. Benjamin EJ, Virani SS, Callaway CW, Chang AR, Cheng S, Chiuve SE, Cushman M, Delling FN, Deo R, de Ferranti SD et al: American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee: Heart disease and stroke statistics—2018 update: A report from the American Heart Association. Circulation 137: e67-e492, 2018.
3. Tournier-Lasserve E: New players in the genetics of stroke. N Engl J Med 347: 1711-1712, 2002.
4. Bak S, Gaist D, Sindrup SH, Skytte A and Christensen K: Genetic liability in stroke: A long-term follow-up study of Danish twins. Stroke 33: 769-774, 2002.
5. Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35-41, 1993.
6. Jerrard-Dunne P, Cloud G, Hassan A and Markus HS: Evaluating the genetic component of ischemic stroke subtypes: A family history study. Stroke 34: 1364-1369, 2003.
7. Bevan S, Traylor M, Adib-Samii P, Malik R, Paul NL, Jackson C, Farrell M, Rothwell PM, Sudlow C, Dighans M, et al: Genetic heritability of ischemic stroke and the contribution of previously reported candidate gene and genomewide associations. Stroke 43: 3161-3167, 2012.
8. Falconi GJ, Malik R, Dighans M and Rosand J: Current concepts and clinical applications of stroke genetics. Lancet Neurol 13: 405-418, 2014.
9. Malik R and Dighans M: Challenges and opportunities in stroke genetics. Cardiovasc Res 14, Mar 18, 2018 (Epub ahead of print).
10. Gretarsdottir S, Thorleifsson G, Manolescu A, Styrkarsdottir U, Helgadottir A, Gwinnupremlaj R, Smith AV, Adams HH et al; GARNET Collaborative Research Group, Wellcome Trust Case Control Consortium 2 (WTCCC2); International Stroke Genetics Consortium: Burden of risk alleles for hypertension increases risk of intracerebral hemorrhage. N Engl J Med 344: 1450-1460, 2012.
11. Alberts MJ, McCarron MO, Hoffmann KL and Graffagnino C: Familial clustering of intracerebral hemorrhage: A prospective study in North Carolina. Neuroepidemiology 21: 18-21, 2002.
12. Falcone GJ, Bifft A, Devan WJ, Jagiella JM, Schmidt H, Kissela B, Hanley DF, Jackson CA, Giralt-Steinhauer E, Folsom AR et al; International Stroke Genetics Consortium; Neurology Working Group of the CHARGE Consortium, NINDS Stroke Genetics Network (SiGN): UK Young Lacunar DNA Study; MEGASTROKE Consortium; MEGASTROKE Consortium: Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke traits. Nat Genet 50: 524-537, 2018.
13. Holliday EG, Maguire JM, Evans TJ, Kobar SA, Janes J, Sturw JW, Hankey GJ, Baker R, Golledge J, Parsons MW, et al; Australian Stroke Genetics Collaborative; International Stroke Genetics Consortium; Wellcome Trust Case Control Consortium 2: Common variants at 6p21.1 are associated with large artery atherosclerotic stroke. Nat Genet 44: 1147-1151, 2012.
14. Bellenguez C, Bevan S, Gwinnupremlaj R, Spencer CC, Burgess AI, Pirinen M, Jackson CA, Traylor M, Strange A, Su Z, et al; International Stroke Genetics Consortium (ISGC); Wellcome Trust Case Control Consortium 2 (WTCCC2); International Stroke Genetics Consortium: Genetic risk factors for ischaemic stroke and its subtypes (the METASTROKE collaboration): A meta-analysis of genome-wide association studies. Lancet Neurol 11: 951-962, 2012.
15. Kilarski LL, Achterberg S, Devan WJ, Traylor M, Malik R, Lindgren A, Pare G, Sharma P, Slowik A, Thijs V, et al; International Stroke Genetics Consortium, the METASTROKE Consortium, and the International Stroke Genetics Consortium: Meta-analysis of more than 17,000 cases of ischaemic stroke reveals a novel association at 12q24.12, Neurology 83: 678-685, 2014.
16. Chauhan G, Arnold CR, Chu AY, Fornage M, Reyahi A, Bis JC, Havulinna AS, Sargurupremraj M, Smith AV, Adams HH et al; Neurology Working Group of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium, the Stroke Genetics Network (SiGN), and the International Stroke Genetics Consortium (ISGC): Identification of additional risk loci for stroke and small vessel disease: A meta-analysis of genome-wide association studies. Lancet Neurol 15: 695-707, 2016.
24. O'Donnell HC, Rosand J, Knudsen KA, Furie KL, Segal AZ, Chiu RI, Ikeda D and Greenberg SM: Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage. N Engl J Med 347: 2040-2045, 2002.

25. Woo D, Falcone DJ, Gev, Devan WJ, DeFaire U, Pedersen NL, Christensen K, Mason CE, Choi M, Foroud T, Lai D, Koller D, Van't Hof F, Kurki MI, Anderson CS, Anderson CD, Brouwers HB, Valant V, Battey TW, et al; International Stroke Genetics Consortium: Common variation in COL4A1/COL4A2 is associated with sporadic cerebral small vessel disease. Neurology 84: 918-926, 2015.

26. Matsushita T, Yamazaki K, Ohnishi Y, Saito S, Matsushita K, Hirakawa Y, Hata J, Amitani H, Doi Y, Ninomiya T, Kitazono T, Iiyashi S, et al; Functional SNP of ARHGFP10 confers risk of atherothrombotic disease. J Hum Genet 51: 137-145, 2012.

27. Low SK, Takahashi A, Cha PC, Zembutsu H, Kamatani N, Kubo M and Nakamura Y: Genome-wide association study for intracranial aneurysm in the Japanese population identifies three candidate susceptible loci and a functional genetic variant at EDRN. Hum Mol Genet 21: 2102-2110, 2012.

28. Cheng YC, Cole JW, Kittner SJ and Mitchell BD: Genetics of ischemic stroke in young adults. Circ Cardiovasc Genet 7: 383-392, 2014.

29. Brass LM, Isaacsohn JL, Merikangas KR and Robinette CD: A study of twins and siblings. Stroke 25: 221-223, 1994.

30. Woo D, Sekar P, Chakraborty R, Haverbusch MA, Flaherty ML, Kissela BM, Kleinendorf D, Schneider A, Khoury J, Sauerbeck LR, et al; Genetic epidemiology of intracerebral hemorrhage. J Stroke Cerebrovasc Dis 14: 259-243, 2005.

31. Sundquist J, Li X, Sundquist K and Hemminki K: Risks of subarachnoid hemorrhage in siblings: A nationwide epidemiological study from Sweden. Neuroepidemiology 29: 178-184, 2007.

32. Yamada Y, Sakuma J, Takeuchi I, Yasukochi Y, Kato K, Oguri M, Fujimaki T, Horibe H, Muramatsu M, Sawabe M, et al; Identification of six polymorphisms as susceptibility loci for ischemic or hemorrhagic stroke by exome-wide association studies. Int J Mol Med 35: 1189-1198, 2015.

33. Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, et al; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism: An updated definition of stroke for the 21st century: A statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 44: 2064-2089, 2013.

34. Grove ML, Yu B, Cochran BJ, Haritunians T, Bis JC, Taylor KD, Hansen M, Borecki IB, Cupples LA, Fornage M, et al; Best practices and joint calling of the HumanExome BeadChip: The CHARGE Consortium. PLoS One 8: e68095, 2013.

35. Anderson CA, Pettersson FH, Clarke GM, Cardon LR, Morris AP and Zondervan KT: Data sharing practices and joint calling of the HumanExome BeadChip: The CHARGE Consortium. J Med Genet 49: 661-678, 2012.

36. Bakker JS,öder JG, Eriksson JG, Flaherty ML, Foroud T, Koller DL, Lai D, Sauerbeck LR, Anderson C, Ko N, et al: Genome-wide association studies identifies 1q22 as a susceptibility locus for ischemic or hemorrhagic stroke by exome-wide association studies. Int J Mol Med 35: 1189-1198, 2015.

37. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA and Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38: 904-909, 2006.

38. Benjamini Y and Hochberg Y: Controlling the false discovery rate: A practical and powerful approach to multiple testing. J R Stat Soc B 57: 289-300, 1995.

39. Wellcome Trust Case Control Consortium: Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447: 661-678, 2007.

40. Hakonarson H, Grant SF, Bradfield JP, Marchand L, Kim CE, Glessner JT, Grabs R, Casalunovo T, Taback SP, Frackelton EC, et al; Identification of six polymorphisms as susceptibility loci for ischemic or hemorrhagic stroke by exome-wide association studies. Circ Cardiovasc Genet 7: e002293, 2014.

41. Teslovich TM, Musunuru K, Smith AV, Edmondson AC, Stouffian IM, Koseki M, Pirruccello JP, Ripatti S, Chasman DI, et al; Biological, clinical and population relevance of 95 loci for blood lipids. Nature 466: 707-713, 2010.

42. Wain LV, Verwoert GC, O'Reilly PF, Shi G, Johnson T, Johnson AD, Bochud M, Rice KM, Henneman P, Smith AV, et al; LifeLines Cohort Study: EchoGen consortium; AortaGen Consortium; CHARGE Consortium Heart Failure Working Group; KidneyGen consortium; Cardiogenics consortium; Cardiogram: Genome-wide association study identifies six new loci influencing pulse pressure and mean arterial pressure. Nat Genet 43: 1005-1011, 2011.
59. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DJ, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al; CHARGE-HF consortium: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109, 2011.

60. Takeuchi F, Yokota M, Yamamoto K, Nakashima E, Katsuya T, Asano H, Isono M, Nabika T, Sugiyama T, Fujioka A, et al: Genome-wide association study of coronary artery disease in the Japanese. Eur J Hum Genet 20: 333-340, 2012.

61. Lee JY, Lee BS, Shin DJ, Woo Park K, Shin YA, Joong Kim K, Heo L, Young Lee J, Kyoung Kim Y, Jin Kim Y, et al: A genome-wide association study of a coronary artery disease risk variant. J Hum Genet 58: 120-126, 2013.

62. CARDioGRAMplusC4D Consortium, Deloukas P, Kanoni S, Willenborg C, Farrall M, Assimes TL, Thompson JR, Ingelsson E, Saleheen D, Erdmann J, et al: Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet 45: 25-33, 2013.

63. Ehret GB, Munroe PB, Rice KM, Bochud M, Johnson AD, Chasman DJ, Smith AV, Tobin MD, Verwoert GC, Hwang SJ, et al; CHARGE-HF consortium: Genetic variants in novel pathways influence blood pressure and cardiovascular disease risk. Nature 478: 103-109, 2011.

64. Kato N, Takeuchi F, Tabara Y, Kelly TN, Go MJ, Sim X, Tay WT, Chen CH, Zhang Y, Yamamoto K, et al: Meta-analysis of genome-wide association studies identifies common variants associated with blood pressure variation in east Asians. Nat Genet 43: 531-538, 2011.

65. Kim YJ, Go MJ, Hu C, Hong CB, Kim YK, Lee JY, Hwang JY, Oh JH, Kim DJ, Kim NH, et al; MAGIC consortium: Large-scale genome-wide association studies in East Asians identify new genetic loci influencing metabolic traits. Nat Genet 43: 990-995, 2011.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.